PF-Atlas › Clinical Trials › NCT04338802
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19
Nintedanib 150 MG · Phase 2
Registry ID
NCT04338802
Phase
Phase 2
Status
Unknown
Drug / intervention
Nintedanib 150 MG
Sponsor
Huilan Zhang
Start
2020-04-02
About this trial
Nintedanib 150 MG is evaluated in NCT04338802, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Huilan Zhang. Current status: Unknown.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04338802 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.